New antivirals for Hepatitis C - what does the evidence prove?
There ’s been a lot of attention given to the new antirviral drugs which target Hepatitis C - partly because of the burden of infection of the disease, and the lack of a treatment that can be made easily accessible to around the world, and partly because of the incredible cost of a course of treatment.
But a new article on BMJ talks about the... (Source: The BMJ Podcast)
Source: The BMJ Podcast - May 12, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
New antivirals for Hepatitis C - what does the evidence prove?
There ’s been a lot of attention given to the new antirviral drugs which target Hepatitis C - partly because of the burden of infection of the disease, and the lack of a treatment that can be made easily accessible to around the world, and partly because of the incredible cost of a course of treatment.
But a new article on BMJ talks about the uncertainly of that treatment - do we know that the drugs actually clear a HepC infection, and that this will lead to a corresponding decrease in mortality and morbidity?
Janus Jakobsen from the Copenhagen Clinical Trial Unit joins us to discuss what the li terature proves.
Read ...
Source: The BMJ Podcast - May 12, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
New antivirals for Hepatitis C - what does the evidence prove?
There ’s been a lot of attention given to the new antirviral drugs which target Hepatitis C - partly because of the burden of infection of the disease, and the lack of a treatment that can be made easily accessible to around the world, and partly because of the incredible cost of a course of treatment.
But a new article on BMJ talks about the... (Source: The BMJ Podcast)
Source: The BMJ Podcast - May 12, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
New antivirals for Hepatitis C - what does the evidence prove?
There’s been a lot of attention given to the new antirviral drugs which target Hepatitis C - partly because of the burden of infection of the disease, and the lack of a treatment that can be made easily accessible to around the world, and partly because of the incredible cost of a course of treatment.
But a new article on BMJ talks about the uncertainly of that treatment - do we know that the drugs actually clear a HepC infection, and that this will lead to a corresponding decrease in mortality and morbidity?
Janus Jakobsen from the Copenhagen Clinical Trial Unit joins us to discuss what the literature proves.
Read th...
Source: The BMJ Podcast - May 12, 2018 Category: General Medicine Authors: BMJ Group Source Type: podcasts
TWiV 476: In ACOD1 we trust
Nels joins the TWiV team to talk about his work on genomic accordions in vaccinia virus, hepatitis B virus in a 439 year old mummy, and viral induction of energy synthesis by a long noncoding RNA. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Kathy Spindler Guest: Nels Elde Click arrow to play Download TWiV 476 (63 MB .mp3, 105 min) Subscribe (free): iTunes, RSS, email Become a patron of TWiV! Links for this episode ASV 2018: asv.org, asv2018.umd.edu TWiV is a must-listen (WaPo) More on poxvirus accordions (bioRxiv) HBV from a 439 year old mummy (PLoS Path) lncRNA promotes viral repl...
Source: This Week in Virology - MP3 Edition - January 14, 2018 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
California Contagion: How to Control Severe Hepatitis A
Dr Paul Auwaerter discusses California ' s hepatitis A outbreak and the challenges of testing to avoid false-positives. (Source: Medscape Infectious Disease Podcast)
Source: Medscape Infectious Disease Podcast - December 14, 2017 Category: Infectious Diseases Authors: Medscape Source Type: podcasts
Liver disease: The Lancet: November 29, 2017
Martin McKee discusses the final report of theLancet's Commission on liver disease, highlighting the health costs of excess alcohol consumption, obesity, and viral hepatitis. (Source: Listen to The Lancet)
Source: Listen to The Lancet - November 29, 2017 Category: General Medicine Authors: The Lancet Source Type: podcasts
When Is Evidence Enough to Justify Widespread Screening?
Just because we can screen for important diseases like diabetes or hepatitis C — should we? (Source: Medscape Family Medicine Podcast)
Source: Medscape Family Medicine Podcast - November 13, 2017 Category: Primary Care Authors: Medscape Source Type: podcasts
TWiV 466: The Capsid Club
From Indiana University, Vincent and Kathy speak with Tuli Mukhopadhyay, John Patton, and Adam Zlotnick about their careers and their work on alphaviruses, hepatitis B virus, and rotaviruses. Host: Vincent Racaniello and Kathy Spindler Guests: Tuli Mukhopadhyay, John Patton, and Adam Zlotnick Become a patron of TWiV! Links for this episode Mukhopadhyay lab Patton lab Zlotnick lab Tuli on Twitter Palmitoylation of Sindbis virus TF protein (J Virol) Hepatitis B virus structure (Ann Rev Virol) Rotavirus RNA polymerase (Curr Opin Virol) Intro music is by Ronald Jenkees. Send your virology questions and comm...
Source: This Week in Virology - MP3 Edition - November 5, 2017 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Update: Novel treatments for HCC in the era of hepatitis C therapies
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa provides an update in novel treatments for hepatocellular carcinoma (HCC) in the era of hepatitis C...
Author: imedex
Added: 08/14/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 14, 2017 Category: Cancer & Oncology Source Type: podcasts
PodMed – Week of August 14, 2017
This week’s topics include complications of aortic valve surgery, effectiveness of nasal flu vaccination, testing for Epstein Barr virus and nasopharyngeal cancer, and hepatitis C treatment. Program notes: 0:31 How effective is the flu vaccine? 1:31 Reformulation of nasal type 2:27 Studies to find out why nasal isn’t working 3:12 Epstein Barr virus and nasopharyngeal […] (Source: Johns Hopkins Medicine Weekly Health News)
Source: Johns Hopkins Medicine Weekly Health News - August 11, 2017 Category: Consumer Health News Authors: Elizabeth Tracey Johns Hopkins Medicine Tags: All Podcasts Cancer Heart And Vascular Infectious diseases Influenza (flu) PodMed Surgery Source Type: podcasts
TWiV 452: Kiss that frog
Lynda Coughlan joins the weekly virtual bus companions for a discussion of a host defense peptide from frogs that destroys influenza virus, and mouse models for acute and chronic hepacivirus infection. Hosts: Vincent Racaniello, Alan Dove, and Kathy Spindler Guest: Lynda Coughlan  Become a patron of TWiV! Links for this episode Linda on Virus Watch and BSGCT Anti-influenza peptide from frogs (Immunity) Magainins (Wikipedia) Urumi Kathy's defensin paper (PLoS Path) World Hepatitis Day Mouse model for hepacivirus infection (Science) Letters read on TWiV 452 Weekly Science Picks Kathy - US rivers as subway map Lynda -Â...
Source: This Week in Virology - MP3 Edition - July 29, 2017 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Mark S. Sulkowski - Managing Chronic Hepatitis C in the Primary Care Setting: Best Practices From Screening to Treatment
Managing Chronic Hepatitis C in the Primary Care Setting: Best Practices From Screening to Treatment (Source: PeerView CME/CE Audio Podcast - Gastroenterology)
Source: PeerView CME/CE Audio Podcast - Gastroenterology - June 21, 2017 Category: Gastroenterology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
